Sign in to Peak Brain Path
Sign in to access your courses, books, and progress tracker. New here? Signing in creates your account automatically.
Want to explore courses first?
Browse courses and booksSign in to access your courses, books, and progress tracker. New here? Signing in creates your account automatically.
Want to explore courses first?
Browse courses and booksModule 17
Chapter 17 · 2 h · 8 quiz items · pass at 80%
This module opens IQCB Domain IX (Clinical/Forensic), 9% of the exam. It puts the whole course to work in a real clinical workflow and names the conditions where QEEG adds value, the populations that need adjusted interpretation, and the situations where QEEG should not be used at all. The quiz confirms the learner can run the workflow and judge clinical fit.
A referral arrives. A psychiatrist has a patient whose attention complaints have not responded to two stimulant trials, and she wants to know whether the EEG shows anything that would change the plan. That sentence is the start of a clinical QEEG, and it sets the terms for everything that follows: what you record, which database you compare against, what the report can say, and what you must refuse to say. The map is not the deliverable. The answer to a clinical question is the deliverable, and the question shapes the work.
This chapter walks the clinical QEEG from the referral to the consultation note that closes it. It covers who is a candidate and who is not, the conditions where a brain map adds information a clinician could not get otherwise, how to read pediatric and older-adult records against databases that were not built for them, how QEEG sits beside a neuropsychological evaluation, and how to write findings a referrer can act on. It also covers the claims you cannot make, because scope discipline is what separates a clinical QEEG service from a brain-map gift shop.
A clinical QEEG runs through six stages, and competence means handling the handoffs between them, not just the technical middle.
Referral. Someone asks a question. The good referrals are specific: differentiate this dementia, lateralize this seizure focus, tell me whether this concussion left a measurable signature, guide a neurofeedback protocol for this attention profile. The weak referrals are diffuse ("can you map his brain?"), and your first job is to convert them into an answerable question or decline. A QEEG with no question behind it produces a report with no clinical use, and a table of z-scores becomes a Rorschach for whoever reads it next.
Intake. You review history, current medications, prior imaging and EEG, and the presenting complaint, and you screen for the conditions that make a map uninterpretable. Intake is also where you set expectations: what the recording will and will not establish.
Acquisition. Nineteen channels minimum for a database comparison, eyes-closed and eyes-open conditions, often a task condition, recorded to the standard the chosen database requires. The acquisition chapter (Chapter 6) governs this stage. A map recorded out of protocol cannot be compared to a database built under a different protocol, and the whole pipeline downstream inherits that error.
Analysis. Artifact review first, then epoch selection, then the transform, then the database comparison and the phenotype read. The methodology chapters (Chapters 10 through 12) govern this stage. The single most common failure here is reading drowsiness as pathology: a patient who drifts toward stage 1 produces frontal theta and posterior slowing that a careless reader scores as an attention or cognitive finding.
Report. The written document, to IQCB report standards (Chapter 13), scope-limited, with a clinical correlation statement and a disclaimer. The report is the only part of this process the referrer sees.
Consultation. You close the loop with the referring clinician, usually by note and sometimes by conversation, translating the quantitative findings into the clinical decision they bear on. A QEEG that goes into a chart without a consultation has done half its job.
Hold the question from stage one through stage six. When you reach the report and find you are describing patterns that do not speak to the referral, you have either drifted or the recording did not answer the question, and both of those facts belong in the consultation.
Not everyone who is referred should be recorded, and not every recording that is technically clean is clinically interpretable. Intake is where you decide.
The pre-acquisition medication review. Psychoactive medication changes the EEG, and the change is not noise to be subtracted. It is a confound that can mimic or mask the exact pattern the referral asks about. Benzodiazepines drive fast beta activity that reads as cortical hyperarousal. Stimulants suppress frontal theta, so a patient recorded on a morning dose of methylphenidate may show a normalized attention profile that tells you nothing about the unmedicated brain. Sedating antipsychotics and many anticonvulsants increase slow-wave power diffusely. The medication and QEEG chapter (Chapter 14) details these signatures. At intake, you make three decisions: whether a washout is feasible and safe, whether to record on-medication and interpret with explicit acknowledgment of the drug's effect, or whether the medication burden makes a meaningful comparison impossible. You do not make any of those decisions silently. Whatever you choose, the medication list and your reasoning go in the report.
State screening. Sleep deprivation shifts the entire spectrum toward slow activity, and the shift outlasts a single bad night. Caffeine elevates fast frontal power acutely. Acute intoxication or withdrawal distorts the record in ways no database correction repairs. You ask about the last night's sleep, the morning's caffeine, and recent substance use, and you reschedule when the answers tell you the recording will not represent the patient's typical brain.
Contraindications and limits. Some referrals are not QEEG questions. A patient in acute delirium, a patient who cannot tolerate cap placement, a patient whose scalp condition prevents adequate impedance, a patient whose seizure activity needs a clinical EEG with a neurologist reading it rather than a quantitative comparison: these are not candidates for a routine clinical QEEG, or they are candidates for a different study. Recognizing the limit at intake protects the patient from a useless recording and protects you from a report you cannot defend. Adapt this list to your own clinic's intake screen. The contraindications above are common, not exhaustive.
The product of a good intake is a recordable patient, a recordable state, and a clear statement of what the recording can answer. If any of the three is missing, the right move is to fix it or to refer, not to record and hope.
QEEG earns its place in a workup when it supplies information that history, examination, and standard testing do not, or when it converges with them to raise confidence. It does not earn its place by producing a colorful map. The conditions below are where the literature and clinical practice support a real contribution, with the caveat that the strength of evidence varies widely across them and you should represent that variation honestly to referrers.
ADHD. The theta/beta ratio (TBR) is the most studied QEEG metric in attention, with a large literature linking elevated frontal-midline theta relative to beta to inattentive presentations (Monastra et al., 1999; Snyder & Hall, 2006). The clinical reality is more constrained than the early enthusiasm. A meta-analysis found the effect real but heterogeneous, with declining effect sizes in more recent samples and substantial overlap between ADHD and control distributions (Arns et al., 2013). TBR is a group-level marker, not a diagnostic test: it is sensitive but not specific, elevated in a substantial minority of typically developing children as well as in many with ADHD. What QEEG adds in ADHD is not diagnosis. It is subtyping and protocol guidance: distinguishing the slow-frontal hypoarousal pattern from the fast-frontal excess-beta pattern (Clarke et al., 2001), which point toward opposite neurofeedback directions, and providing a baseline against which to track change. Represent it that way and you are on defensible ground. Call it a diagnostic test and you are not.
TBI. This is the condition where QEEG has the strongest quantitative-discriminant literature and, not coincidentally, the most forensic exposure (Chapter 18). Thatcher and colleagues built a discriminant function from EEG coherence, phase, and power measures that separated mild-TBI patients from controls with reported classification accuracy above 90% in the development sample (Thatcher et al., 1989). The acute picture is diffuse slowing with focal delta over a contusion; the subacute and chronic picture is a slower normalization trajectory and persistent coherence disruption over the injured network. What QEEG adds in TBI is documentation of a functional electrophysiological abnormality in a patient whose structural imaging is often normal, which is exactly why it appears in litigation and exactly why the forensic chapter treats its limits at length. Two cautions belong in every TBI QEEG: the discriminant findings have limited independent replication relative to their forensic use, and the same coherence abnormalities are not specific to trauma.
PTSD. The most consistent QEEG association in PTSD is with arousal: elevated high beta and reduced or dysregulated posterior alpha, the electrophysiology of hypervigilance (Begić, Hotujac, & Jokić-Begić, 2001). Begić and colleagues found increased theta over central regions and increased beta (frontal and central) in combat veterans with PTSD relative to controls, with no significant differences in delta or alpha. What QEEG adds is not a PTSD diagnosis, which is clinical, but a description of an arousal phenotype that can guide arousal-targeted intervention and provide a baseline for monitoring treatment response. The honest framing is that the QEEG is consistent with a hyperaroused state and does not establish its cause.
Epilepsy, as an adjunct. Here QEEG supports rather than replaces clinical EEG. The diagnosis of epilepsy and the reading of epileptiform discharges belong to a neurologist reading a clinical EEG, not to a quantitative comparison (Chapter 8). What quantitative methods add is in pre-surgical work: source localization and quantitative asymmetry can support lateralization of a focus already identified clinically, as one input among several in a presurgical evaluation. A QEEG never makes the seizure-focus determination on its own, and a practitioner who implies otherwise has stepped outside both scope and competence.
Dementia differentiation. QEEG contributes to distinguishing dementia subtypes when read alongside the clinical picture and imaging. Alzheimer's disease characteristically shows diffuse slowing with posterior theta and delta and a slowed alpha peak; frontotemporal dementia tends toward an anterior-predominant pattern; Lewy body dementia is associated with prominent slowing and variability (Niedermeyer & Lopes da Silva, 2005). What QEEG adds is a quantitative slowing signature that can support a differential and, in serial recordings, track progression. It does not make the diagnosis, and the early-stage overlap among subtypes is real.
Neurofeedback protocol guidance. This is QEEG's most direct clinical application in a neurofeedback practice: the map identifies candidate targets, the phenotype read translates a deviation into a training direction, and the baseline anchors later comparison. The QEEG-to-protocol chain is the subject of the neurofeedback practitioner companion, not this book, and the boundary matters. This book teaches you to read the map. It does not teach protocol design, and a QEEG report should guide protocol selection, not prescribe it.
Across all six, the discipline is the same. State what the QEEG adds, state the strength of the evidence behind it, and do not let a vivid map carry weight the literature does not support.
A single map is a snapshot. Serial QEEG is the more powerful clinical tool, because change against a patient's own baseline sidesteps the individual-variation problem that limits a single database comparison. When you record the same patient twice, the question shifts from "how does this brain compare to the database mean?" to "how does this brain compare to itself before the intervention?", and the second question is often the one the referrer actually cares about.
Two requirements make a serial comparison interpretable. First, the recordings must be acquired under matched conditions: same montage, same reference, same eyes-closed and eyes-open structure, same time of day where feasible, same medication state or a documented and deliberate change in it. A change in protocol between recordings produces apparent change that is an artifact of method, not a treatment effect. Second, you must know what a meaningful change looks like, which means knowing the test-retest reliability of the metric you are tracking. QEEG metrics differ in stability: posterior alpha peak frequency is among the most stable features, while some power ratios fluctuate more across sessions (Chapter 12). A shift smaller than the metric's own session-to-session variability is not a result, however much a clinician wants it to be.
The clinical uses are concrete. You re-record to document neurofeedback-related change against the trained sites. You re-record to track a TBI normalization trajectory over months. You re-record to monitor an arousal phenotype across a course of treatment for PTSD or anxiety. You re-record, in older adults, to track a slowing trajectory that may signal progression. In each case, the comparison that matters is longitudinal, and the report should present change explicitly: the baseline value, the follow-up value, and a statement about whether the difference exceeds expected measurement variability. Do not let a clinician read normal session-to-session noise as treatment success or failure.
A child's EEG is not a small adult's EEG, and the central interpretive risk in pediatric QEEG is comparing a developing brain against a normative model that does not extend cleanly to its age, or that has too few subjects at that age to be stable.
The maturational facts govern the read. Slow-wave activity is normal and abundant in young children and declines across development. Posterior theta that would be abnormal in an adult is age-appropriate in a child. The posterior dominant rhythm starts slow and climbs toward the adult alpha range across childhood. A frontal theta elevation that looks like an attention finding may be nothing more than the expected slow activity of a young cortex, and the only protection against over-reading it is a database with adequate representation at the child's specific age and strict age-regression. The major databases include pediatric ranges, but the number of subjects thins at the youngest ages, and the normative comparison becomes progressively less stable the younger the child. Check your database's documentation for the age range where subject density drops, and weight the comparison lightly when the child sits at or below that floor.
Two practical rules follow. Read the child against age-matched norms, never against a flat adult cutoff, and state the database's age range and subject density in the report so the referrer knows how much weight the comparison carries. And weight the clinical history more heavily than you would in an adult, because the database is doing less of the work. A developmental QEEG is a clinical-context document with a quantitative supplement, not a quantitative document with a clinical footnote.
At the other end of the lifespan, two facts complicate the read: the EEG slows with normal aging, and older adults carry more medication. Both can manufacture findings that are not pathology.
The aging brain shows a gradual decline in alpha peak frequency and a modest increase in slow activity that is part of normal senescence, not disease (Scally et al., 2018). The interpretive task is to separate normal aging from the slowing that signals mild cognitive impairment or early dementia, and the separation depends on age-appropriate norms and on magnitude: in an older cohort, a small z-score deviation can carry more clinical weight than the same deviation in a young adult, because the age-matched reference distribution is narrower for some features. You read an eighty-year-old against eighty-year-old norms, and you treat a slowed alpha peak in that context as a finding worth following serially rather than a one-time verdict.
Polypharmacy is the second complication, and it is additive. An older adult on a benzodiazepine for sleep, an anticholinergic for bladder, and an antidepressant for mood carries three sources of EEG slowing at once, and the summed effect can read as cognitive decline when it is pharmacology. The medication review at intake is not optional in this population. It is the difference between a defensible interpretation and a misattribution. When the medication burden is heavy and a washout is unsafe, the honest report states that the slowing reflects both whatever the brain is doing and the cumulative drug effect, and declines to assign the finding to a disease process the recording cannot isolate.
QEEG and neuropsychological testing measure different things, and the clinical power is in the combination, not in either alone. The QEEG measures resting electrical organization. The neuropsychological battery measures performance under standardized cognitive demand. When they converge, confidence rises. When they diverge, the divergence is informative, and learning to read it is a clinical skill the field guide develops at length (its performance-validation chapter is the reference here).
Convergence is the straightforward case. A frontal theta elevation on QEEG, paired with elevated omission errors and high reaction-time variability on a continuous performance test, paired with a patient who reports sustained-attention failure, is three independent data streams pointing at one mechanism. That is a strong formulation, and a referrer can act on it.
Divergence is where judgment earns its keep. A flagged QEEG with clean neuropsychological performance suggests the spectral pattern is individual variation, or compensated, or state-driven, not a confirmed functional deficit, and the report should say so rather than treating the map as the truth and the testing as the error. A clean QEEG with impaired performance suggests dysfunction that resting spectral analysis does not index, which narrows the differential toward task-dependent or demand-dependent mechanisms. In neither direction does the QEEG override the performance data. The resting map adds to the clinical picture. It does not determine it. A practitioner who lets a vivid z-score table outvote an objective performance deficit has the hierarchy backward.
The integration rule is simple to state and easy to violate under the pull of a striking map: functional data take precedence over spectral patterns that do not manifest functionally. Write the QEEG into the formulation as one stream among three (brain, performance, presentation), and report the divergences honestly. The convergences make the case. The divergences keep you from overstating it.
The consultation note is where the QEEG becomes clinically useful, and it is a different document from the formal report. The report is the scope-limited, defensible, archival record. The note is the translation: what the findings mean for the decision the referrer faces, in language a busy clinician can use in the time they have.
A useful consultation note leads with the answer to the referral question, not with the methods. If the psychiatrist asked whether the EEG would change the medication plan, the first sentence addresses that, and the supporting findings follow. It characterizes the magnitude of findings in plain terms, sparing the clinician a cascade of z-scores, and it states confidence honestly: a Grade B attention phenotype that converges with performance testing is described differently from an isolated borderline deviation. It flags what the QEEG cannot establish as clearly as what it can, so the referrer does not infer more than the data support. And it makes referral recommendations within scope: when a finding warrants neurological workup, the note says so and routes it, rather than implying the QEEG has already done the neurologist's job.
What the note does not do is diagnose, prescribe, or mandate treatment. "The QEEG is consistent with an underarousal attention pattern and provides a baseline for monitoring" is a clinical contribution. "The patient has ADHD and should start neurofeedback" is a scope violation wearing a consultation note's clothing. The line between them is the same line the report holds, and you hold it in both documents.
Patients see the map, and the map is persuasive in ways the data do not warrant. Reds and blues on a topographic display communicate urgency and certainty that a table of probabilistic deviations does not earn, and the patient conversation is where you manage that gap. The clinical aim is an accurate understanding the patient can use, not a dramatic image they will over-interpret or carry to the next provider as a diagnosis.
Show what supports the clinical formulation and skip the rest. A patient does not need the full z-score table, and handing it over invites them to read every flagged metric as a problem, including the ones that are statistical noise. Explain findings in functional terms tied to their actual complaint: an underarousal pattern means the frontal cortex is running cool when it should be engaged, which fits the focus difficulty they came in with. State the uncertainty in plain language, because a patient who believes the map proved a diagnosis is harder to treat and more likely to misrepresent the finding elsewhere. And do not let the patient leave with the impression that the brain map is a verdict. It is one input into a clinical picture that also includes their history, their testing, and their treating clinician's judgment.
The patient-facing explanation is a different register from the clinician-facing one, and the field's consumer companion (Neurofeedback: Explained) carries the full scripts. The standard here is the same as everywhere else in the workflow: accurate, scope-limited, and honest about what the colorful image can and cannot establish.
A competent QEEG practice is defined as much by the recordings it declines as by the ones it performs. QEEG adds noise rather than signal in several situations, and recognizing them is part of the skill.
Do not record when there is no clinical question, because the output will be a table of deviations in search of a meaning, and someone downstream will supply a meaning the data do not support. Do not substitute QEEG for the study that is actually indicated: a suspected seizure disorder needs a clinical EEG read by a neurologist, not a quantitative comparison, and a suspected structural lesion needs imaging. Do not record a patient whose state or medication burden makes the result uninterpretable when the confound cannot be removed. An uninterpretable map is worse than no map, because it carries the authority of a measurement without the validity of one. Do not use QEEG as a standalone diagnostic test for any psychiatric condition, because no QEEG metric has the specificity that role requires, and the regulatory and professional consensus has not endorsed it for that use. The AAN and ACNS assessment of QEEG, published in the late 1990s and not formally superseded, did not recommend QEEG for routine clinical diagnostic use; no subsequent major-society guideline has reversed that position. And do not let QEEG drive a treatment decision that the convergent clinical picture does not also support; a flagged map without symptom and performance corroboration is a hypothesis, not an indication.
The throughline of this chapter is that the clinical value of QEEG is real, conditional, and easy to overstate. It is real in subtyping and protocol guidance for attention, in documenting functional injury in TBI, in characterizing arousal in PTSD, in supporting a dementia differential, in lateralization as a presurgical adjunct, and in monitoring change against a patient's own baseline. It is conditional on a clean recording, an answerable question, an appropriate database, and honest scope. And it is easy to overstate every time a vivid map invites a claim the literature will not back. The patient in the first paragraph came with a specific question about a specific decision. The work is done when you have answered that question, stated what the answer rests on, and handed the referring clinician something they can act on without inheriting a claim you cannot defend. That answer, written into a consultation note that respects its own limits, is the deliverable. The map was only ever the means.